Cargando…

(698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients

PURPOSE: Multiple variants of SARS-CoV-2 have been documented throughout the COVID-19 pandemic. Mutations that lead to these variants can affect viral spread, disease severity, and the efficacy of vaccines and therapeutics. Lung transplant (LT) recipients (LTRs) are at high risk of COVID-19-related...

Descripción completa

Detalles Bibliográficos
Autores principales: Sindu, D., Razia, D., Grief, K., Padiyar, J., Schaheen, L., Omar, A., Walia, R., Smith, M.A., Bremner, R.M., Tokman, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068055/
http://dx.doi.org/10.1016/j.healun.2023.02.712
_version_ 1785018605717422080
author Sindu, D.
Razia, D.
Grief, K.
Padiyar, J.
Schaheen, L.
Omar, A.
Walia, R.
Smith, M.A.
Bremner, R.M.
Tokman, S.
author_facet Sindu, D.
Razia, D.
Grief, K.
Padiyar, J.
Schaheen, L.
Omar, A.
Walia, R.
Smith, M.A.
Bremner, R.M.
Tokman, S.
author_sort Sindu, D.
collection PubMed
description PURPOSE: Multiple variants of SARS-CoV-2 have been documented throughout the COVID-19 pandemic. Mutations that lead to these variants can affect viral spread, disease severity, and the efficacy of vaccines and therapeutics. Lung transplant (LT) recipients (LTRs) are at high risk of COVID-19-related morbidity and mortality; however, disease severity may differ between SARS-CoV-2 variants. We sought to describe the clinical outcomes of LTRs with COVID-19 at different stages of the pandemic. METHODS: We performed a retrospective chart review of LTRs with COVID-19 and categorized them into 4 groups according to the prevalent variant on the date of the positive test. Chi-square and non-parametric binomial exact tests were used for comparative analyses. RESULTS: Since March 2020, 195 LTRs at our institute developed COVID-19; the median age was 66.6 years (58.7-72); 114 (58.5%) were male; 190 (97.4%) had received a bilateral LT; 106 (54.4%) had diabetes; 63 (32.3%) were obese; and 145 (74.4%) had chronic kidney disease with an eGFR <60. The most common immunosuppressive regimen included mycophenolate mofetil, tacrolimus, and prednisone (n=142; 72.8%). The median percent predicted FEV1 was 81% (IQR 63-96) and the median time from LT to COVID-19 diagnosis was 37.3 months (IQR 18.5-66.7). Rates of hospitalization, ICU admission, need for mechanical ventilation, and death were significantly lower for the Omicron variant than the original strain, the Alpha variant, and the Delta variant. However, there was no difference in length of hospital stay, development of extrapulmonary end-organ dysfunction, or persistent drop in spirometric flows (Table 1). Lastly, the utilization of vaccination and monoclonal antibodies grew over time and likely contributed to reduced COVID-19 severity in the latter part of the pandemic. CONCLUSION: COVID-19 continues to drive morbidity and mortality among LTRs; however, the severity of disease is lower with the omicron variant.
format Online
Article
Text
id pubmed-10068055
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-100680552023-04-03 (698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients Sindu, D. Razia, D. Grief, K. Padiyar, J. Schaheen, L. Omar, A. Walia, R. Smith, M.A. Bremner, R.M. Tokman, S. J Heart Lung Transplant Article PURPOSE: Multiple variants of SARS-CoV-2 have been documented throughout the COVID-19 pandemic. Mutations that lead to these variants can affect viral spread, disease severity, and the efficacy of vaccines and therapeutics. Lung transplant (LT) recipients (LTRs) are at high risk of COVID-19-related morbidity and mortality; however, disease severity may differ between SARS-CoV-2 variants. We sought to describe the clinical outcomes of LTRs with COVID-19 at different stages of the pandemic. METHODS: We performed a retrospective chart review of LTRs with COVID-19 and categorized them into 4 groups according to the prevalent variant on the date of the positive test. Chi-square and non-parametric binomial exact tests were used for comparative analyses. RESULTS: Since March 2020, 195 LTRs at our institute developed COVID-19; the median age was 66.6 years (58.7-72); 114 (58.5%) were male; 190 (97.4%) had received a bilateral LT; 106 (54.4%) had diabetes; 63 (32.3%) were obese; and 145 (74.4%) had chronic kidney disease with an eGFR <60. The most common immunosuppressive regimen included mycophenolate mofetil, tacrolimus, and prednisone (n=142; 72.8%). The median percent predicted FEV1 was 81% (IQR 63-96) and the median time from LT to COVID-19 diagnosis was 37.3 months (IQR 18.5-66.7). Rates of hospitalization, ICU admission, need for mechanical ventilation, and death were significantly lower for the Omicron variant than the original strain, the Alpha variant, and the Delta variant. However, there was no difference in length of hospital stay, development of extrapulmonary end-organ dysfunction, or persistent drop in spirometric flows (Table 1). Lastly, the utilization of vaccination and monoclonal antibodies grew over time and likely contributed to reduced COVID-19 severity in the latter part of the pandemic. CONCLUSION: COVID-19 continues to drive morbidity and mortality among LTRs; however, the severity of disease is lower with the omicron variant. Published by Elsevier Inc. 2023-04 2023-04-03 /pmc/articles/PMC10068055/ http://dx.doi.org/10.1016/j.healun.2023.02.712 Text en Copyright © 2023 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sindu, D.
Razia, D.
Grief, K.
Padiyar, J.
Schaheen, L.
Omar, A.
Walia, R.
Smith, M.A.
Bremner, R.M.
Tokman, S.
(698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
title (698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
title_full (698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
title_fullStr (698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
title_full_unstemmed (698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
title_short (698) Covid-19 is Less Severe with the Omicron Variant Compared to Prior Variants and the Original Sars-Cov-2 Strain in Lung Transplant Recipients
title_sort (698) covid-19 is less severe with the omicron variant compared to prior variants and the original sars-cov-2 strain in lung transplant recipients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068055/
http://dx.doi.org/10.1016/j.healun.2023.02.712
work_keys_str_mv AT sindud 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT raziad 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT griefk 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT padiyarj 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT schaheenl 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT omara 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT waliar 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT smithma 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT bremnerrm 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients
AT tokmans 698covid19islessseverewiththeomicronvariantcomparedtopriorvariantsandtheoriginalsarscov2straininlungtransplantrecipients